Previous 10 | Next 10 |
2024-04-23 09:13:24 ET DENVER, Colo., Apr 23, 2024 ( 247marketnews.com )- Palisade Bio, Inc. (Nasdaq: PALI ) stated that the Company entered into a strategic collaboration with Strand Life Sciences, aimed at advancing precision medicine for ulcerative colitis (UC) therapy. Palis...
– Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics – Partnership marks a significant value-driving milestone in Palisade Bio's mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers ...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 50.1% to $0.1783 on volume of 599,794,977 shares WiSA Technologies Inc. (WISA) rose 248.6% to $6.1 on volume of 197,912,579 shares PROSHARES TRUST (SQQQ) rose 0.0% to $11.44 on volume of 182,001,060 shar...
2024-04-16 12:40:38 ET More on Mid-day movers & stocks. Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript Jaguar Health shareholders approve reverse stock split BioSig Technologies to reduce its internal workforce to cut down costs Seeking Alpha...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 37.1% to $0.1629 on volume of 102,747,129 shares WiSA Technologies Inc. (WISA) rose 69.1% to $2.96 on volume of 24,734,833 shares Peraso Inc. (PRSO) rose 37.0% to $1.7393 on volume of 23,546,162 shares ...
2024-04-16 09:55:21 ET More on Palisade Bio Palisade Bio stock slides 8% amid colitis drug presentation Palisade Bio announces 1-for-15 reverse stock split Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade Bio F...
2024-04-16 09:29:31 ET DENVER, Colo., Apr 16, 2024 ( 247marketnews.com )- Palisade Bio, Inc. (Nasdaq: PALI ), Brera Holding (NASDAQ: BREA ), Peraso Inc. (NASDAQ: PRSO ), BioRestorative Therapies, Inc. (NASDAQ: BRTX ), and Intra-Cellular Ther...
2024-04-16 08:44:59 ET DENVER, Colo., Apr 16, 2024 ( 247marketnews.com )- Palisade Bio, Inc. (Nasdaq: PALI ) stated that it successfully completed its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-...
Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a bi...
– Live webcast with members of Palisade Bio management on Tuesday, April 16 th at 12:00 PM ET Carlsbad, CA, April 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company...
News, Short Squeeze, Breakout and More Instantly...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition o...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...